Tools   Select Another Resource Report Type

https://www.corengi.com/

A comprehensive, free, and interactive platform to help individuals discover more about clinical trials that may be appropriate for them for a variety of diseases. The platform allows stakeholders within the clinical trials community (investigators, site personnel, sponsors, and disease advocates) to engage with potential enrollees and educate them about specific clinical trials. They have identified some of the most commonly used criteria for the clinical trials in each disease. Using these criteria, they developed a questionnaire for a single disease. Then, looking at just those questions, they can start to get a sense of which clinical trials might be appropriate for a particular person which is a helpful to start to narrow down the list of potentially appropriate trials. All clinical trials that are posted on www.clinicaltrials.gov for the diseases that Corengi covers will be on the website.

Proper citation: Corengi (RRID:SCR_003942) Copy   

•   Source: SciCrunch Registry

http://danstem.ku.dk/

Center consisting of 9 research groups who all address basic questions in stem cell and developmental biology with the overall aim of developing new stem cell-based therapeutic approaches for diabetes and cancer. DanStem comprises two sections: * The Novo Nordisk Foundation Section for Basic Stem Cell Biology (BasicStem) * The Section for Strategic Translational Stem Cell Research and Therapy (TransStem) DanStem was established as a result of a series of international recruitments coupled with internationally recognized research groups focused on insulin producing beta cells and cancer research already located at the University of Copenhagen. They all have well-established, international collaborations and actively participate in several international scientific consortia. DanStem is also active in training undergraduates, PhD students and postdocs.

Proper citation: DanStem (RRID:SCR_004021) Copy   

•   Source: SciCrunch Registry

http://www.mcewencentre.com/

Center aiming to be a catalyst for regenerative medicine by facilitating collaboration, supporting research, and promoting awareness of the field. The center includes 15 scientists at five Toronto hospitals, as well as the University of Toronto, currently working to accelerate the development of more effective treatments for conditions such as heart disease, diabetes, respiratory disease and spinal cord injury. They collaborate with many other research institutions throughout North America, Europe and the Asia / Pacific region. The research is powered by a team of recent doctoral graduates recruited from around the world that are selected through a competitive process. They are a critical tool for supporting the work of McEwen Centre, allowing them to find medical breakthroughs faster.

Proper citation: McEwen Centre for Regenerative Medicine (RRID:SCR_004020) Copy   

•   Source: SciCrunch Registry

http://www.autoimmunitycenters.org/

Nine centers that conduct clinical trials and basic research on new immune-based therapies for autoimmune diseases. This program enhances interactions between scientists and clinicians in order to accelerate the translation of research findings into medical applications. By promoting better coordination and communication, and enabling limited resources to be pooled, ACEs is one of NIAID''''s primary vehicles for both expanding our knowledge and improving our ability to effectively prevent and treat autoimmune diseases. This coordinated approach incorporates key recommendations of the NIH Autoimmune Diseases Research Plan and will ensure progress in identifying new and highly effective therapies for autoimmune diseases. ACEs is advancing the search for effective treatments through: * Diverse Autoimmunity Expertise Medical researchers at ACEs include rheumatologists, neurologists, gastroenterologists, and endocrinologists who are among the elite in their respective fields. * Strong Mechanistic Foundation ACEs augment each clinical trial with extensive basic studies designed to enhance understanding of the mechanisms responsible for tolerance initiation, maintenance, or loss, including the role of cytokines, regulatory T cells, and accessory cells, to name a few. * Streamlined Patient Recruitment The cooperative nature of ACEs helps scientists recruit patients from distinct geographical areas. The rigorous clinical and basic science approach of ACEs helps maintain a high level of treatment and analysis, enabling informative comparisons between patient groups.

Proper citation: Autoimmunity Centers of Excellence (RRID:SCR_006510) Copy   

•   Source: SciCrunch Registry

https://www.t1dgc.org/

Data and biological samples were collected by this consortium organizing international efforts to identify genes that determine an individual risk of type 1 diabetes. It originally focused on recruiting families with at least two siblings (brothers and/or sisters) who have type 1 diabetes (affected sibling pair or ASP families). The T1DGC completed enrollment for these families in August 2009. They completed enrollment of trios (father, mother, and a child with type 1 diabetes), as well as cases (people with type 1 diabetes) and controls (people with no history of type 1 diabetes) from populations with a low prevalence of this disease in January 2010. T1DGC Data and Samples: Phenotypic and genotypic data as well as biological samples (DNA, serum and plasma) for T1DGC participants have been deposited in the NIDDKCentral Repositories for future research.

Proper citation: Type 1 Diabetes Genetics Consortium (RRID:SCR_001557) Copy   

•   Source: SciCrunch Registry

http://www.diabetestrialnet.org/

International network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes. It is conducting clinical trials with researchers from 18 Clinical Centers in the United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand. In addition, more than 150 medical centers and physician offices are participating in the TrialNet network. Studies are available for people newly diagnosed with type 1 diabetes, as well as for relatives of people with type 1 diabetes who are at greater risk of developing the disease. This NIH-sponsored clinical trials network conducts studies designed to evaluate new approaches to prevent or ameliorate type 1 diabetes specifically by interdicting the type 1 diabetes disease process. These include interventions designed to decrease beta-cell destruction and/or enhance beta-cell survival. Studies are conducted in non-diabetic persons at risk of type 1 diabetes in an effort to delay the development of type 1 diabetes as a clinical disease; or (if initiated prior to appearance of autoimmunity) in an effort to delay the appearance of autoimmunity; or in individuals with type 1 diabetes who are either newly diagnosed or have evidence of sustained beta cell function. Studies include long-term follow-up of subjects developing type 1 diabetes. The TrialNet network also supports natural history and genetics studies in populations screened for or enrolled in studies conducted by the TrialNet study group. In addition, TrialNet will evaluate methodologies that enhance the conduct of clinical trials interdicting the type 1 diabetes disease process.

Proper citation: Type 1 Diabetes TrialNet (RRID:SCR_001508) Copy   

•   Source: SciCrunch Registry

http://www.immunetolerance.org/

International clinical research consortium dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. They aim to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. In particular, they aim to: * Establish new tolerance therapeutics * Develop a better understanding of the mechanisms of immune function and disease pathogenesis * Identify new biomarkers of tolerance and disease Their goals are to identify and develop treatment game changers for tolerance modulating therapies for the treatment of immune mediated diseases and disabling conditions, and to conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders. In the Immune Tolerance Network's (ITN) unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. They develop and fund clinical trials and mechanistic studies in partnership. Their development model is a unique, interactive process. It capitalizes on their wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions worldwide. This model gives investigators special insight into developing high quality research studies. The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington.

Proper citation: Immune Tolerance Network (ITN) (RRID:SCR_001535) Copy   

•   Source: SciCrunch Registry

http://teddy.epi.usf.edu/

International consortium of six centers assembled to participate in the development and implementation of studies to identify infectious agents, dietary factors, or other environmental agents, including psychosocial factors, that trigger type 1 diabetes in genetically susceptible people. The coordinating centers recruit and enroll subjects, obtaining informed consent from parents prior to or shortly after birth, genetic and other types of samples from neonates and parents, and prospectively following selected neonates throughout childhood or until development of islet autoimmunity or T1DM. The study tracks child diet, illnesses, allergies and other life experiences. A blood sample is taken from children every 3 months for 4 years. After 4 years, children will be seen every 6 months until the age of 15 years. Children are tested for 3 different autoantibodies. The study will compare the life experiences and blood and stool tests of the children who get autoantibodies and diabetes with some of those children who do not get autoantibodies or diabetes. In this way the study hopes to find the triggers of T1DM in children with higher risk genes.

Proper citation: TEDDY (RRID:SCR_000383) Copy   

•   Source: SciCrunch Registry

http://www2.niddk.nih.gov/Research/Resources/ObesityResources.htm

THIS RESOURCE IS NO LONGER IN SERVICE, documented May 23, 2017. This website contains resources for obesity researchers including: Obesity Databases, Registries and Information; Obesity Multicenter Clinical Research; Obesity Basic Research Networks; Obesity Reagents; Obesity Services; Obesity Standardization Programs; Obesity Tissues, Cells, Animals; Obesity Useful Tools.

Proper citation: NIDDK- National Institute of Diabetes and Digestive and Kidney Diseases Obesity Resources (RRID:SCR_003074) Copy   

•   Source: SciCrunch Registry

https://sites.google.com/ucsd.edu/drc/home

Research center across five institutions for clinical research in diabetes. Collaborators include UC San Diego's School of Medicine, Salk Institute, Cedars-Sinai Medical Center, UC Los Angeles' School of Medicine, and LA Biomedical Research Center.

Proper citation: University of California San Diego - University of California Los Angeles Diabetes Research Center (RRID:SCR_015100) Copy   

•   Source: SciCrunch Registry

http://www.gcdtr.org

Research center for translational research on type 2 diabetes with a strong emphasis on translation into real world health care settings and communities.

Proper citation: Georgia Center for Diabetes Translation Research (RRID:SCR_015185) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/

Research center which operates in collaboration with the University of Alabama Birmingham Comprehensive Diabetes Center to promote excellence in diabetes research and patient care. The DRC supports the areas of animal physiology, human biology and intervention and translational research. It focuses on developing new methods to treat, prevent, and ultimately cure diabetes and its complications.

Proper citation: University of Alabama at Birmingham Diabetes Research Center (RRID:SCR_015107) Copy   

•   Source: SciCrunch Registry

http://diabetesresearch.med.umich.edu

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on June 30,2023. Multidisciplinary diabetes unit of the University of Michigan funded by the National Institute of Diabetes and Digestive and Kidney Diseases/National Institute of Health. The goal of the MDRC is to establish, promote, and enhance multidisciplinary and collaborative basic biomedical and clinical research among member investigators studying diabetes, its complications, and related endocrine and metabolic disorders.

Proper citation: Michigan Diabetes Research Center (RRID:SCR_015112) Copy   

•   Source: SciCrunch Registry

http://www.baderc.org

Consortium of laboratory-based and clinical investigators who research etiology, pathogenesis, treatment and cure of type 1 and type 2 diabetes, and their associated microvascular and atherosclerotic complications.

Proper citation: Boston Area Diabetes Endocrinology Research Center (RRID:SCR_015072) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/diabetes-research/

Research center that facilitates the research of diabetes and related studies in obesity, metabolism and endocrinology

Proper citation: Einstein-Mount Sinai Diabetes Research Center (RRID:SCR_015070) Copy   

•   Source: SciCrunch Registry

https://www.niddk.nih.gov/research-funding/research-programs/hematology-centers

Online portal with thorough information about hematology research centers and cores. Each entry details the center's research aims, its activities and core services, and links to pilot programs.

Proper citation: Hematology Centers (RRID:SCR_015321) Copy   

•   Source: SciCrunch Registry

https://cdtr.wustl.edu

Research center for diabetes that offers regional and national resources to investigators for translation interventions into healthcare settings, communities, and populations at-risk. The CDTR supports studies investigating the root causes of diabetes and disparities as well as the prevention of obesity as a major contributing cause of Type 2 diabetes.

Proper citation: Washington University Center for Diabetes Translation Research (RRID:SCR_015204) Copy   

•   Source: SciCrunch Registry

http://chicagodiabetesresearch.org

Center to improve the lives of people with diabetes and people at risk for diabetes through prevention, improved diabetes care, and community empowerment.

Proper citation: Chicago Center for Diabetes Translation Research (RRID:SCR_015179) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/diabetes-translational-research/

Center designed to increase collaboration and enhance communication among diabetes researchers from multiple institutions and diverse disciplines

Proper citation: New York Regional Center for Diabetes Translation Research (RRID:SCR_015174) Copy   

•   Source: SciCrunch Registry

http://derc.yale.edu

University-affiliated center that promotes research in diabetes and related metabolic and endocrine disorders at Yale University.

Proper citation: Yale Diabetes Research Center (RRID:SCR_015142) Copy   

•   Source: SciCrunch Registry